The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Increased Risk of Non-Fatal Myocardial Infarction Following Testosterone Therapy Prescription in Men
Open accessAbstract
BACKGROUND: An association between testosterone therapy (TT) and cardiovascular disease has been reported and TT use is increasing rapidly. METHODS: We conducted a cohort study of the risk of acute non-fatal myocardial infarction (MI) following an initial TT prescription (N = 55,593) in a large health-care database. We compared the incidence rate of MI in the 90 days following the initial prescription (post-prescription interval) with the rate in the one year prior to the initial prescription (pre-prescription interval) (post/pre). We also compared post/pre rates in a cohort of men prescribed phosphodiesterase type 5 inhibitors (PDE5I; sildenafil or tadalafil, N = 167,279), and compared TT prescription post/pre rates with the PDE5I post/pre rates, adjusting for potential confounders using doubly robust estimation. RESULTS: In all subjects, the post/pre-prescription rate ratio (RR) for TT prescription was 1.36 (1.03, 1.81). In men aged 65 years and older, the RR was 2.19 (1.27, 3.77) for TT prescription and 1.15 (0.83, 1.59) for PDE5I, and the ratio of the rate ratios (RRR) for TT prescription relative to PDE5I was 1.90 (1.04, 3.49). The RR for TT prescription increased with age from 0.95 (0.54, 1.67) for men under age 55 years to 3.43 (1.54, 7.56) for those aged ≥ 75 years (p trend = 0.03), while no trend was seen for PDE5I (p trend = 0.18). In men under age 65 years, excess risk was confined to those with a prior history of heart disease, with RRs of 2.90 (1.49, 5.62) for TT prescription and 1.40 (0.91, 2.14) for PDE5I, and a RRR of 2.07 (1.05, 4.11). DISCUSSION: In older men, and in younger men with pre-existing diagnosed heart disease, the risk of MI following initiation of TT prescription is substantially increased.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Some epidemiological studies have reported an increase in cardiovascular mortality related to TRT while others have not been able to establish a correlation between the two [19,20].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hulley, S. (1998) · JAMA · doi:10.1001/jama.280.7.605 · Cited by 6,216 · cited 1×
“[26–29] The mechanisms linking estrogens to thrombotic events may be related to markers of activated coagulation, decreased coagulation inhibitors, and activated protein C resistance [30].”
Doubly robust estimation in missing data and causal inference models
Bang, H., & Robins, J. M. (2005) · Biometrics · doi:10.1111/j.1541-0420.2005.00377.x · Cited by 1,998 · cited 1×
“[12] These estimates are unconfounded by the adjustment variables if the prescriptionodds model or the outcome-regression model is specified correctly.”
BackgroundPostmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause
Rossouw, J. E., Prentice, R. L., Manson, J. E., Wu, L., Barad, D., Barnabei, V. M., Ko, M., LaCroix, A. Z., Margolis, K. L., & Stefanick, M. L. (2007) · JAMA · doi:10.1001/jama.297.13.1465 · Cited by 1,741 · cited 1×
“[26–29] The mechanisms linking estrogens to thrombotic events may be related to markers of activated coagulation, decreased coagulation inhibitors, and activated protein C resistance [30].”
BackgroundAdverse Events Associated with Testosterone Administration
Basaria, S., Coviello, A. D., Travison, T. G., Storer, T. W., Farwell, W. R., Jette, A. M., Eder, R., Tennstedt, S., Ulloor, J., Zhang, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000485 · Cited by 1,494 · cited 3×
“[4] This was followed by a meta-analysis of a number of a number of very small trials in predominantly older men which also suggested excess cardiovascular risk.”
BackgroundMethodMajor Risk Factors as Antecedents of Fatal and Nonfatal Coronary Heart Disease Events
Greenland, P. (2003) · JAMA · doi:10.1001/jama.290.7.891 · Cited by 1,053
Hirano, K., & Imbens, G. W. (2001) · Health Services and Outcomes Research Methodology · doi:10.1023/a:1020371312283 · Cited by 1,039 · cited 1×
“[11] This weighting aligns the distribution in the comparison cohort of the variables used in the prescription-probability model to match the distribution in the TT prescription cohort.”
MethodVigen, R. (2013) · JAMA · doi:10.1001/jama.2013.280386 · Cited by 1,003 · cited 1×
“[6] In the two studies assessing timing of the increase, it was noted to appear very soon following initiation of therapy.”
BackgroundCardiovascular Events and Intensity of Treatment in Polycythemia Vera
Marchioli, R., Finazzi, G., Specchia, G., Cacciola, R. R., Cavazzina, R., Cilloni, D., Stefano, V. D., Elli, E. M., Iurlo, A., Latagliata, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208500 · Cited by 871 · cited 1×
“Exogenous testosterone (TT) is associated with physiologic changes that predispose to clotting and thrombotic disorders including increased blood pressure [18], polycythemia [19], reductions in HDL cholesterol [18,20], and hyperviscosity of the blood and platelet aggregation.”
Adverse Effects of Testosterone Therapy in Adult Men: A Systematic Review and Meta-Analysis
Fernández-Balsells, M. M., Murad, M. H., Lane, M., Lampropulos, J. F., Albuquerque, F., Mullan, R. J., Agrwal, N., Elamin, M. B., Gallegos-Orozco, J. F., Wang, A. T., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2575 · Cited by 713
Thrombotic stroke and myocardial infarction with hormonal contraception
Lidegaard, Ø., Løkkegaard, E., Jensen, A., Skovlund, C. W., & Keiding, N. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1111840 · Cited by 607 · cited 1×
“[26–29] The mechanisms linking estrogens to thrombotic events may be related to markers of activated coagulation, decreased coagulation inhibitors, and activated protein C resistance [30].”
Background
Research works printed but not linked: 1
- Rothman KJ, Greenland S, Lash TL (2008) Modern epidemiology. Philadelphia, Pa.; London: Lippincott Williams & Wilkins.
Cited by
Sorted by citations
Items 601–700 of 732
Hypogonadism in Male Sexual Dysfunction
Stoian, D. L., Mozos, I. M., Craina, M. L., Paul, C., Velea, I. P., Schiller, A., & Crăciunescu, M. (2017) · InTech eBooks · doi:10.5772/intechopen.69107 · Cited by 1
Testosteron replasmanı ve kardiyovasküler yan etkileri
Atan, A., Yeşil, S., & Polat, F. (2017) · Androloji Bülteni · doi:10.24898/tandro.2017.28199 · Cited by 1
Metabolic Abnormalities and Drugs
Rowan, C. J. (2018) · Oxford University Press eBooks · doi:10.1093/med/9780190225483.003.0023 · Cited by 1
Predictive Factors of Efficacy Maintenance after Testosterone Treatment Cessation
Park, M. G., Yeo, J. K., Park, S., Na, W., & Moon, D. G. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8020151 · Cited by 1
Age-Related Testosterone Deficiency Merits Treatment
Traish, A. M. (2021) · Androgens Clinical Research and Therapeutics · doi:10.1089/andro.2020.0019 · Cited by 2
“Both studies were fraught with methodological and statistical analyses that were not validated at the time 42,43 ; (3) one meta-analysis, which included studies that do not meet the criteria for inclusion.”
Therapeutic Strategies to Spinal Cord Injury
Jendelová, P. (2018) · MDPI eBooks · doi:10.3390/books978-3-03897-407-9 · Cited by 1
Testosterone in Transgender Population
Cocchetti, C., & Fisher, A. D. (2021) · Springer eBooks · doi:10.1007/978-3-030-77111-9_9 · Cited by 1
López, D. S., Kim, H., Polychronopoulou, E., Taha, S. A., Tsilidis, K. K., Tezanos, A. G. V., Peek, M. K., Gilani, S. A., Khera, M., Baillargeon, J., et al. (2022) · Cancer Epidemiology · doi:10.1016/j.canep.2022.102172 · Cited by 1
Research update for articles published in EJCI in 2013
Abbate, R., Al‐Daghri, N. M., Andreozzi, P., Borregaard, N., Can, G., Caridi, G., Carstensen‐Kirberg, M., Cioni, G., Conte, E., Cuomo, R., et al. (2015) · European Journal of Clinical Investigation · doi:10.1111/eci.12512 · Cited by 1
Commentary on "Late-onset hypogonadism - beyond testosterone"
Hackett, G. I. (2014) · Asian Journal of Andrology · doi:10.4103/1008-682x.137679 · Cited by 1
Hackett, G. I. (2017) · Wiley eBooks · doi:10.1002/9781118954621.ch13 · Cited by 1
Testosterone replacement therapy
Surampudi, V., & Swerdloff, R. S. (2015) · Cardiovascular Endocrinology · doi:10.1097/xce.0000000000000058 · Cited by 1
Weiß, A. G. (2024) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-10273 · Cited by 1
Borges, J. Y. V. (2024) · Research Square · doi:10.21203/rs.3.rs-5134020/v1 · Cited by 1
Re: Risk of Myocardial Infarction in Older Men Receiving Testosterone Therapy
Dohle, G. R., & Dinkelman‐Smit, M. (2015) · European Urology · doi:10.1016/j.eururo.2015.06.035
“Instead, two recent studies indicated a higher risk of cardiovascular events in men receiving testosterone supplementation [3,4].”
BackgroundInfluentialHeidelbaugh, J. J. (2014) · Journal of Men s Health · doi:10.1089/jomh.2014.0077
“7 Several trials have suggested an increased risk of CVD mortality, although with methodological flaws, inappropriate patient stratification, and inappropriate risk comparisons, 8,9 and without primary endpoints ofCVD.”
Evidence is king, but reader beware: the misinterpretation of studies
Sigman, M. (2014) · Fertility and Sterility · doi:10.1016/j.fertnstert.2014.03.023
Schubert, M. (2015) · Info Diabetologie · doi:10.1007/s15034-015-0516-2
Más controversias en el tratamiento con testosterona
Rajmil, O. (2014) · Revista Internacional de Andrología · doi:10.1016/j.androl.2014.10.001
Testosterone e apparato cardiovascolare
Aversa, A., Francomano, D., Isidori, A. M., Fabbri, A., Jannini, E. A., & Lenzi, A. (2014) · L Endocrinologo · doi:10.1007/s40619-014-0068-z
“[10] e pubblicato su PLoS One, ha riportato un maggiore tasso di infarto miocardico associato alle prescrizioni di T, ma mancava un gruppo di controllo, pertanto non è stato in grado di fornire alcuna indicazione definitiva.”
BackgroundWidespread Use of Performance-Enhancing Drugs—An Inconvenient Truth
Hayes, F. J. (2014) · Endocrine Reviews · doi:10.1210/er.2014-1047
Malignant medication? Testosterone and cancer
Pastuszak, A. W. (2015) · British Journal of Urology · doi:10.1111/bju.12822
Cardiovascular Benefits of Testosterone Replacement Therapy in the Andropausal Male
Vatti, S. K., Madanieh, R., Madanieh, A., Kosmas, C. E., & Vittorio, T. J. (2015) · Health · doi:10.4236/health.2015.79135 · Cited by 1
“A study by Finkle et al included a cohort of 55,593 patients prescribed TRT [17].”
MethodFaraday, N. R., & Dobs, A. S. (2014)
Low Testosterone: When to Treat?
Grossmann, M. (2014) · The Endocrine Society eBooks · doi:10.1210/mtp3.9781936704835.ch48
Low T? Late Onset Hypogonadism
Huang, C. (2014) · ScholarWorks -A service of University of Vermont Libraries (University of Vermont)
Elliott, J. (2016) · uO Research (University of Ottawa) · doi:10.20381/ruor-5176
“198 AMS score >36 6 mo Placebo (179) Testogel 1%, gel, 50 mg/d (183) 62.”
BackgroundPlasma Testosterone and Dihydrotestosterone as Markers of Heart Disease and Mortality in Older Men
Yeap, B. B. (2015) · Springer eBooks · doi:10.1007/978-94-007-7741-5_38-1
Survey of the Literature December 2015
Saitz, T. R. (2015) · Sexual Medicine · doi:10.1002/sm2.88
Tadrous, M., Martins, D., Lee, K., Knowles, S. R., Mamdani, M., Juurlink, D. N., & Gomes, T. (2016) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.2016.1167600
Overselling hysteria, dangerously: the media coverage of testosterone therapy in men
Vance, J. (2015) · OpenBU (Boston University)
Füeßl, H. S. (2014) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-014-2805-4
Ho, C. C. K., & Tan, H. M. (2015) · Heart and Metabolism
Controversy over Cardiovascular Risks of Testosterone Therapy
Carter, D. (2015) · AJN American Journal of Nursing · doi:10.1097/01.naj.0000465018.88189.53
Testosterone and cardiovascular disease
Yuen, K. C. J. (2014) · Cardiovascular Endocrinology · doi:10.1097/xce.0000000000000038
Another Study Suggests Excess Cardiovascular Risk with Testosterone
Brett, A. S. (2014) · Journal watch · doi:10.1056/nejm-jw.na33607
Heidelbaugh, J., Grech, A., & Miner, M. (2016) · Springer eBooks · doi:10.1007/978-3-319-26091-4_13
Re: Effects of Testosterone Treatment in Older Men
Seftel, A. D. (2016) · The Journal of Urology · doi:10.1016/j.juro.2016.05.062
Low Testosterone and the Metabolic Syndrome
Winters, S. (2015) · Springer eBooks · doi:10.1007/978-1-4939-2059-4_36
Scovell, J. M., Ramasamy, R., & Lipshultz, L. I. (2015) · Urology · doi:10.1016/j.urology.2015.03.054
Male menopause – similarities and differences with the female menopause
Carruthers, M. E. (2015) · Cambridge University Press eBooks · doi:10.1017/cbo9781316091821.029
Sex Hormones and Cognitive Aging
McCarrey, A. C., Kitner‐Triolo, M. H., & Resnick, S. M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-411469-2.00004-2
Hormonal Evaluation and Therapy of Erectile Dysfunction
Hockenberry, M. S., & Masson, P. (2016) · Springer eBooks · doi:10.1007/978-3-319-31587-4_7
Testosterone and cardiovascular disease – what is the story?
Morgentaler, A. (2016) · Trends in Urology & Men s Health · doi:10.1002/tre.545
Improving the management of testosterone deficiency
Mayor, S. (2016) · Prescriber · doi:10.1002/psb.1506 · Cited by 1
AACE/ACE Disease State Clinical Review
Davies, L., Haymart, M. R., Chen, A. Y., Goldenberg, D., Morris, J. H., Ogilvie, J. B., Terris, D. J., Netterville, J. L., Wong, R. J., & Randolph, G. W. (2015)
Surprising Factor Behind Sudden Cardiac Arrest
Faloon, W. W. (2015)
Gianatti, E. (2016) · Minerva Access (University of Melbourne)
Rastrelli, G., & Maggi, M. (2017) · Endocrinology · doi:10.1007/978-3-319-29456-8_32-1
Functional Hypogonadism: Diabetes Mellitus, Obesity, Metabolic Syndrome, and Testosterone
Meirelles, R. M. D. R. (2017) · Springer eBooks · doi:10.1007/978-3-319-46086-4_7
Testosterone Therapy: Injectable Androgens
Yassin, A. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-46086-4_12
Testosterone, metabolism, and cardiovascular disease
Yuen, K. C. J., & Krentz, A. J. (2015) · Cardiovascular Endocrinology · doi:10.1097/xce.0000000000000054
Defining the best candidates for testosterone replacement?
Krakowsky, Y., & Grober, E. D. (2015) · Cardiovascular Endocrinology · doi:10.1097/xce.0000000000000059
Escalante, C. L., Gómez‐Pérez, R., & Briceño, Y. (2015)
Erectile Dysfunction as a Cardiovascular Risk Marker
Teo, C., & Lau, W. (2017) · The Singapore Family Physician · doi:10.33591/sfp.44.1.u6
Psychosocial and Endocrine Antecedents of Responses to Social-Evaluative Stress
Knight, E. L. (2017) · Scholars' Bank (University of Oregon)
Treating Aging with Testosterone.
Fugh‐Berman, A. (2017) · PubMed
Donner, D. G. (2015) · Griffith Research Online · doi:10.13140/rg.2.1.1191.1761
Hipogonadismo associado à obesidade: efeitos do tratamento com citrato de clomifeno
Soares, A. H. (2018) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2018.tde-13062018-074535
Resumen de la Guía de Práctica Clínica de Disfunción Eréctil – Sociedad Colombiana de Urología
Ceballos, M., & Arcila, J. (2018) · Revista Urología Colombiana / Colombian Urology Journal · doi:10.1055/s-0038-1676044
Effects of testosterone levels on mortality and cardiovascular risk in men with Type 2 diabetes
Muraleedharan, V. (2018) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
Bhattacharya, R. K. (2015) · Urology · doi:10.1016/j.urology.2015.03.053
Sotirov, S., Penev, P., & Kirova, D. G. (1989) · PubMed
Endocrine Health and Healthy Aging
Mirza, F., Taxel, P., & Luthra, P. (2019) · Springer eBooks · doi:10.1007/978-3-030-06200-2_18
The investigation of miR-499 in apoptosis of cardiomyocytes in blood serum of MI patients
Hasanzadeh, H., Ahmadizadeh, C., & Ghorbani, A. (2019) · فصلنامه علوم پزشکی دانشگاه آزاد اسلامی واحد پزشکی تهران · doi:10.29252/iau.29.2.155
La, M. K. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/z65y-xj23
Sex Steroid Hormones and Osteosarcopenia
Girgis, C. M. (2019) · Springer eBooks · doi:10.1007/978-3-030-25890-0_8
Opioid-Induced Androgen Deficiency in Veterans With Chronic Nonmalignant Pain.
Brooks, A. T., Nazario, M., DiScala, S., Cuevas-Trisan, R. L., & Meléndez-Benabe, J. (2015) · Europe PMC (PubMed Central)
Pastuszak, A. W. (2014) · The Journal of Urology · doi:10.1016/j.juro.2014.07.130
Kolenburg, J., & de Vries, P. (2020) · Tijdschrift voor Urologie · doi:10.1007/s13629-020-00292-w
Tsuchiya, T., Inukai, T., Hara, K., Takebayashi, K., & Hashimoto, K. (2020) · Gene Technology · doi:10.35248/2329-6682.20.9.150
“A retrospective national cohort study showed the association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels [61], indicating that excessive testosterone exposure may be detrimental to the cardiovascular system [62-64].”
BackgroundTestosterone Use and Abuse : Methodological Aspects in Forensic Toxicology and Clinical Diagnostics
Lood, Y. (2021) · Linköping University medical dissertations · doi:10.3384/diss.diva-173146
Mielewczyk, J., Świętochowska, E., Ostrowska, Z., & Miczek, I. (2021) · Postępy Higieny i Medycyny Doświadczalnej · doi:10.5604/01.3001.0014.8308
Testosterone therapy increases risk of non-fatal MI
(2014) · Reactions Weekly · doi:10.1007/s40278-014-9489-5
Risks of Testosterone Treatment
Dobs, A. S., & Yalamanchi, S. (2022) · doi:10.1093/med/9780198870197.003.0490
Yang, H., Ho, C., Zhao, P. T., Su, D., & Seftel, A. D. (2016) · Springer eBooks · doi:10.1007/978-1-4939-4928-1_12
Alabrah, P. W., Wankasi, M. M., Borobuebi, O. J., & Agoro, E.-Y. S. (2022) · Open Journal of Endocrine and Metabolic Diseases · doi:10.4236/ojemd.2022.123006
Hormone Replacement Therapy in Men
Pham, C. H., Wang, C., & Swerdloff, R. S. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.99449-2
Mirone, V. G., & Rocca, R. L. (2020) · Springer eBooks · doi:10.1007/978-3-030-28599-9_9
Faculty Opinions recommendation of Treatment of men for "low testosterone": A systematic review.
Minhas, S., Tharakan, T., & Miah, S. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.726764636.793556540
Cardiovascular Issues in the Treatment of Erectile Dysfunction
Jackson, G., Kirby, M. G., & Hackett, G. I. (2016) · Springer eBooks · doi:10.1007/978-3-319-31587-4_9
Hypogonadism and Testosterone Therapy in Elderly Men
Yeap, B. B. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.66168-8
Testosterone therapy: increased risk of CV events
(2014) · Reactions Weekly · doi:10.1007/s40278-014-8882-4
Preinbergs, J. K. (2022) · Linköping University medical dissertations · doi:10.3384/9789179294274
Jósvai, A., Török, M., Hetthéssy, J. R., Mátrai, M., Monori-Kiss, A., Makk, J., Vezér, M., Sára, L., Szabó, I. V., Székács, B., et al. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e11533
Testosterone Therapy in Oncologic Patients
Solsrud, E., Louters, M. M., & Pearlman, A. M. (2023) · Current Sexual Health Reports · doi:10.1007/s11930-022-00351-w
Seneszenz und Altershypogonadismus
Rolf, C., Zitzmann, M., & Nieschlag, E. (2023) · Springer Reference Medizin · doi:10.1007/978-3-662-61904-9_25-1
Seneszenz und Altershypogonadismus
Rolf, C., Zitzmann, M., & Nieschlag, E. (2023) · Springer Reference Medizin · doi:10.1007/978-3-662-61901-8_25
Male Hypogonadism and Aging: An Update
Iglesias, P., Núñez, A., & Díez, J. J. (2023) · Springer eBooks · doi:10.1007/978-3-031-31501-5_9
Functional Hypogonadism: Diabetes Mellitus, Obesity, Metabolic Syndrome, and Testosterone
Meirelles, R. M. D. R. (2023) · Springer eBooks · doi:10.1007/978-3-031-31501-5_8
Cardiovascular safety of testosterone replacement therapy
Čapka, D. (2023) · Urologie pro praxi · doi:10.36290/uro.2023.070
Haddad, D. E., Kim, H., Polychronopolou, E., Baillargeon, J., Tezanos, A. G. V., Kuo, Y., Gilani, S., Khalife, W. I., & López, D. S. (2023) · Research Square · doi:10.21203/rs.3.rs-3530181/v1
Kavoussi, P. K., & Machen, G. L. (2023) · Cambridge University Press eBooks · doi:10.1017/9781009197533.033
Relação da Testosterona com a Obesidade e a Hipertensão Arterial
Póvoa, R. (2024) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20240138
Hypogonadism and testosterone therapy in elderly men
Yeap, B. B. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00046-7
Borges, J. Y. V. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4984259
Testosterontherapie: injizierbare Androgene
Yassin, A. A. (2024) · Springer eBooks · doi:10.1007/978-3-031-65245-5_15
Testosteron und kardiovaskuläre Effekte
Yeap, B. B. (2024) · Springer eBooks · doi:10.1007/978-3-031-65245-5_19
Männlicher Hypogonadismus und Alterung: ein Update
Iglesias, P., Núñez, A., & Díez, J. J. (2024) · Springer eBooks · doi:10.1007/978-3-031-65245-5_9
Metadata
- Authors
- Finkle, W. D., Greenland, S., Ridgeway, G. K., Adams, J. L., Frasco, M. A., Cook, M. B., Fraumeni, J. F., & Hoover, R. N.
- Affiliations
- University of California, Los Angeles (US)
- National Cancer Institute (US)
- Corresponding author
- Finkle, William D.
- Hoover, Robert N.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-01-29
- Volume
- 9
- Issue
- 1
- Pages
- e85805
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3905977
- OpenAlex
- W2156204904
- Cited by
- 735
- References
- 31
- Citations by year
- 2026: 21 · 2025: 34 · 2024: 33 · 2023: 42 · 2022: 45 · 2021: 32 · 2020: 41 · 2019: 52 · 2018: 69 · 2017: 87 · 2016: 79 · 2015: 112 · 2014: 86
- FWCI
- 97.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, public-domain)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, public-domain)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, public-domain)
- Figshare (submittedVersion, cc-by)
- Funders
- National Institutes of Health
- National Cancer Institute
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- testosterone replacement therapy, myocardial infarction, cardiovascular risk, phosphodiesterase-5 inhibitors, sildenafil, tadalafil, men, older men, heart disease history, drug safety, adverse drug reactions
- MeSH terms
- Tadalafil, Sildenafil Citrate, Age Factors, Aged, Carbolines, Humans, Male, Middle Aged, Myocardial Infarction, Piperazines, Purines, Risk, Sulfones, Testosterone, Prescription Drugs, Phosphodiesterase 5 Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
